Trending NewsTrending NewsMost-Downgraded StocksMost-DowngradedNYSE:BSX Boston Scientific (BSX) Stock Price, News & Analysis $41.55 -0.64 (-1.52%) Closing price 10/7/2026 03:58 PM EasternExtended Trading$41.59 +0.04 (+0.10%) As of 05:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Boston Scientific Stock (NYSE:BSX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Boston Scientific alerts:Sign Up Key Stats Today's Range$41.50▼$42.5250-Day Range$41.55▼$52.0252-Week Range$41.50▼$105.65Volume15.87 million shsAverage Volume20.43 million shsMarket Capitalization$60.21 billionP/E Ratio16.82Dividend YieldN/APrice Target$66.31Consensus RatingModerate Buy Company Overview Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation. The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management. Boston Scientific also provides technologies used in the diagnosis and treatment of structural heart conditions and other complex diseases. Founded in 1979, Boston Scientific is headquartered in Marlborough, Massachusetts, and serves hospitals, healthcare professionals and patients in markets around the world. The company operates through a global network of research, manufacturing and commercial operations. Michael F. Mahoney serves as chairman and chief executive officer.AI Generated. May Contain Errors. Read More Boston Scientific Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks97th Percentile Overall ScoreBSX MarketRank™: Boston Scientific scored higher than 97% of companies evaluated by MarketBeat, and ranked 9th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingBoston Scientific has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 22 buy ratings, 6 hold ratings, and 2 sell ratings.Upside PotentialBoston Scientific has a consensus price target of $66.31, representing about 59.6% upside from its current price of $41.55.Amount of Analyst CoverageBoston Scientific has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Boston Scientific's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth3.38% Earnings GrowthEarnings for Boston Scientific are expected to grow by 3.38% in the coming year, from $3.25 to $3.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Boston Scientific is 16.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.86.Price to Earnings Ratio vs. SectorThe P/E ratio of Boston Scientific is 16.82, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.56.Price to Earnings Growth RatioBoston Scientific has a PEG Ratio of 1.01. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioBoston Scientific has a P/B Ratio of 2.52. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Boston Scientific's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.22% of the float of Boston Scientific has been sold short.Short Interest Ratio / Days to CoverBoston Scientific has a short interest ratio ("days to cover") of 2.35, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Boston Scientific has recently decreased by 3.46%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBoston Scientific does not currently pay a dividend.Dividend GrowthBoston Scientific does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment-0.03 News SentimentBoston Scientific has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Boston Scientific this week, compared to 8 articles on an average week.Search Interest89 people have searched for BSX on MarketBeat in the last 30 days. This is an increase of 7% compared to the previous 30 days.MarketBeat FollowsOnly 20 people have added Boston Scientific to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of Boston Scientific in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $9,385,210.00 in company stock, which represents 0.0156% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Boston Scientific insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,385,210.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders0.34% of the stock of Boston Scientific is held by insiders.Percentage Held by Institutions89.07% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Boston Scientific's insider trading history. Receive BSX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BSX Stock News HeadlinesBoston Scientific (NYSE:BSX) Sets New 52-Week Low - Here's Why1 hour ago | americanbankingnews.comBarclays initiates coverage of Boston Scientific with equal-weight4 hours ago | msn.comWall Street Legend: “Global Market Freeze Coming”Dr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehman Brothers, is warning of a developing financial crisis. The New York Times has credited him as among the first to see the dangers ahead, and Forbes dubbed him Mr. Independence. He says this emerging situation could trigger a chain reaction across banks and markets. Watch his free video breakdown and see the five steps he outlines for investors. | Weiss Ratings (Ad)Boston Scientific Names Joseph Fitzgerald as COO4 hours ago | finance.yahoo.comBoston Scientific Names Fitzgerald Executive Vice President & COO In New Operating RestructureOctober 7 at 3:22 PM | rttnews.comBoston Scientific (NYSE: BSX) names Fitzgerald COO, splits into 3 segmentsOctober 7 at 8:02 AM | americanbankingnews.comBoston Scientific Announces New COO and Operating StructureOctober 7 at 6:30 AM | tipranks.comBoston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating OfficerOctober 7 at 6:00 AM | prnewswire.comSee More Headlines BSX Stock Analysis - Frequently Asked Questions How have BSX shares performed this year? Boston Scientific's stock was trading at $95.29 at the start of the year. Since then, BSX stock has decreased by 56.4% and is now trading at $41.5470. How were Boston Scientific's earnings last quarter? Boston Scientific Corporation (NYSE:BSX) issued its earnings results on Wednesday, July, 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts' consensus estimates of $0.83 by $0.03. The company's revenue for the quarter was up 7.5% on a year-over-year basis. Read the conference call transcript. Is Boston Scientific buying back stock? Boston Scientific's Board of Directors approved a stock buyback plan on Monday, May 18th 2026, which authorizes the company to buy back $5,000,000,000 in shares, according to EventVestor. This means that the company could reacquire up to 6.4% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's management believes its stock is undervalued. Does Boston Scientific have any subsidiaries? Boston Scientific subsidiaries include these companies: VertiFlex, BTG, Augmenix, Veniti, Claret Medical, Cryterion Medical, nVision Medical, and more. Who are Boston Scientific's major shareholders? Boston Scientific's top institutional investors include Congress Asset Management Co. (0.01%), North Point Portfolio Managers Corp OH (0.01%), Neville Rodie & Shaw Inc. and Persium Advisors LLC. Insiders that own company stock include Michael F Mahoney, Daniel J Brennan, Joseph Michael Fitzgerald, Vance R Brown, Eric Francis Yves Thepaut, Edward J Ludwig, Edward J Ludwig, Wendy Carruthers, Jeffrey B Mirviss, Ellen M Zane, Arthur C Butcher, John Bradley Sorenson, David C Habiger, Yoshiaki Fujimori, Cheryl Pegus and Charles J Dockendorff. View institutional ownership trends. How do I buy shares of Boston Scientific? Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Boston Scientific own? Based on aggregate information from My MarketBeat watchlists, some other companies that Boston Scientific investors own include BlackRock (BLK), Broadcom (AVGO), ServiceNow (NOW), UnitedHealth Group (UNH), The Goldman Sachs Group (GS), NVIDIA (NVDA) and Illinois Tool Works (ITW). Company Calendar Last Earnings7/29/2026Today10/07/2026Next Earnings (Estimated)10/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 3 days ago, BSX's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:BSX CIK885725 Webwww.bostonscientific.com Phone(508) 683-4000Fax508-683-5675Employees59,000Year Founded1979Price Target and Rating Average Price Target for Boston Scientific$66.31 High Price Target$118.00 Low Price Target$48.00 Potential Upside/Downside+59.6%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage30 Analysts Profitability EPS (Trailing Twelve Months)$2.47 Trailing P/E Ratio16.82 Forward P/E Ratio12.78 P/E Growth1.01Net Income$2.90 billion Net Margins17.50% Pretax Margin18.39% Return on Equity19.28% Return on Assets10.89% Debt Debt-to-Equity Ratio0.43 Current Ratio1.24 Quick Ratio0.74 Sales & Book Value Annual Sales$20.07 billion Price / Sales3.00 Cash Flow$3.98 per share Price / Cash Flow10.45 Book Value$16.49 per share Price / Book2.52Miscellaneous Outstanding Shares1,449,230,000Free Float1,444,303,000Market Cap$60.21 billion OptionableOptionable Beta0.58 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NYSE:BSX) was last updated on 10/8/2026 by MarketBeat.com Staff. From Our PartnersChina ATTACK on American Dollar set for 11/12/2026A former Wall Street Journal personal finance expert warns China may be setting the stage for a major move aga...International Living | SponsoredAnthropic’s $40 million midterm moveAnthropic, creator of Claude, has committed $40 million to Public First Action, a nonpartisan group advocating...The Oxford Club | SponsoredWhat Could Change After November 3rd?Democrats are favored to take the House on November 3rd, needing just five seats to flip the chamber. The last...USA Capital Gold | SponsoredA dividend every week of the yearMost dividend stocks pay quarterly, leaving long stretches of silence between paydays. For investors covering ...Market Savvy | Sponsored“Whoever wins AI, wins”Jason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as Novemeber. It...Weiss Ratings | SponsoredThey're not telling you how bad this could getValuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...Parkview Capital Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Boston Scientific Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Boston Scientific With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
